Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Arthritis Research & Therapy
Erschienen in: Arthritis Research & Therapy 3/2008

01.06.2008 | Review

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?

verfasst von: Josef S Smolen, Daniel Aletaha, Johannes Grisar, Kurt Redlich, Günter Steiner, Oswald Wagner

Erschienen in: Arthritis Research & Therapy | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid arthritis is a heterogeneous disease with respect to clinical manifestations, serologic abnormalities, joint damage and functional impairment. Predicting outcome in a reliable way to allow for strategic therapeutic decision-making as well as for prediction of the response to the various therapeutic modalities available today, especially biological agents, would provide means for optimization of care. In the present article, the current information on biological and clinical markers related to disease activity and joint damage as well as for predictive purposes is reviewed. It will be shown that the relationship of many biomarkers with disease characteristics is confounded by factors unrelated to the disease, and that only few biomarkers exist with some predictive value. Moreover, clinical markers appear of equal value as biomarkers for this purpose, although they likewise have limited capacity in these regards. The analysis suggests the search for better markers to predict outcomes and therapeutic responsiveness in rheumatoid arthritis needs to be intensified.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Heijde van der DM, van Leeuwen MA, van Riel PL, Koster AM, van't Hof MA, van Rijswijk MH, Putte van de LB: Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. 1992, 35: 26-34. 10.1002/art.1780350105.CrossRefPubMed
2.
Plant MJ, Jones PW, Saklatvala J, Ollier WE, Dawes PT: Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol. 1998, 25: 417-426.PubMed
3.
Masi AT: Articular patterns in the early course of rheumatoid arthritis. Am J Med. 1983, 75 (6A): 16-26. 10.1016/0002-9343(83)90471-0.CrossRefPubMed
4.
Steiner G, Smolen JS: Autoantibodies in rheumatoid arthritis. Rheumatoid Arthritis. Edited by: Firestein GS, Panayi GS, Wollheim FA. 2006, Oxford: Oxford University Press, 193-198. 2
5.
Pincus T, Brooks RH, Callahan LF: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med. 1994, 120: 26-34.CrossRefPubMed
6.
Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM: Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 1999, 42: 1854-1860. 10.1002/1529-0131(199909)42:9<1854::AID-ANR9>3.0.CO;2-F.CrossRefPubMed
7.
Aletaha D, Smolen J, Ward MM: Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum. 2006, 54: 2784-2792. 10.1002/art.22052.CrossRefPubMed
8.
Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO, Hughes M, Altman D, Buyse M, Galbraith S, Wells G: Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol. 2007, 34: 607-615.PubMed
9.
Aletaha D, Smolen JS: The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am. 2006, 32: 9-44. 10.1016/j.rdc.2005.09.005.CrossRefPubMed
10.
Temple RJ: A regulatory authority's opinion about surrogate endpoints. Clinical Measurement in Drug Evaluation. Edited by: Nimmo WS, Tucker GT. 1995, New York: John Wiley and Sons Inc, 5-23.
11.
NIH White Paper: Biomarkers, the Osteoarthritis Initiative. 2000, Bethesda: National Institutes of Health
12.
Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO, Hughes M, Altman D, Buyse M, Galbraith S, Wells G: Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol. 2007, 34: 607-615.PubMed
13.
Heijde van der D, Simon L, Smolen J, Strand V, Sharp J, Boers M, Breedveld F, Weisman M, Weinblatt M, Rau R, Lipsky P: How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum. 2002, 47: 215-218. 10.1002/art.10181.CrossRefPubMed
14.
Landewe R, Geusens P, Boers M, van der HD, Lems W, te KJ, Koppele J, Linden van der S, Garnero P: Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum. 2004, 50: 1390-1399. 10.1002/art.20222.CrossRefPubMed
15.
Landewe RB, Geusens P, Heijde Van der DM, Boers M, Linden van der SJ, Garnero P: Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: a longitudinal analysis. Ann Rheum Dis. 2006, 65: 40-44. 10.1136/ard.2004.035196.PubMedCentralCrossRefPubMed
16.
Visvanathan S, Marini JC, Smolen JS, Clair EW, Pritchard C, Shergy W, Pendley C, Baker D, Bala M, Gathany T, Han J, Wagner C: Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol. 2007, 34: 1465-1474.PubMed
17.
Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, Robins S, Griffiths I: Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum. 2007, 56: 3236-3247. 10.1002/art.22923.CrossRefPubMed
18.
den Broeder AA, Joosten LA, Saxne T, Heinegård D, Fenner H, Miltenburg AM, Frasa WL, van Tits LJ, Buurman WA, van Riel PL, Putte van de LB, Barrera P: Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis. 2002, 61: 311-318. 10.1136/ard.61.4.311.PubMedCentralCrossRefPubMed
19.
Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001, 159: 1689-1699.PubMedCentralCrossRefPubMed
20.
Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G: Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest. 2002, 110: 1419-1427.PubMedCentralCrossRefPubMed
21.
Teitelbaum SL: Bone resorption by osteoclasts. Science. 2000, 289: 1504-1508. 10.1126/science.289.5484.1504.CrossRefPubMed
22.
Geusens PP, Landewé RB, Garnero P, Chen D, Dunstan CR, Lems WF, Stinissen P, Heijde van der DM, Linden van der S, Boers M: The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 2006, 54: 1772-1777. 10.1002/art.21896.CrossRefPubMed
23.
Skoumal M, Haberhauer G, Kolarz G, Hawa G, Woloszczuk W, Klingler A: Serum cathepsin K levels of patients with long-standing rheumatoid arthritis: correlation with radiological destruction. Arthritis Res Ther. 2005, 7: R65-R70. 10.1186/ar1461.PubMedCentralCrossRefPubMed
24.
Grisar J, Kapral T, Gonda G, Stamm T, Smolen JS, Aletaha D: Short term responsiveness of biomarkers to prednisolone in patients with active rheumatoid arthritis [abstract]. Ann Rheum Dis. 2006, 65 (Suppl II): 171-
25.
Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, Chesnut CH, Eyre DR: Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res. 1994, 9: 135-142.CrossRefPubMed
26.
Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S: Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 1998, 63: 102-106. 10.1007/s002239900497.CrossRefPubMed
27.
Andersson ML, Petersson IF, Karlsson KE, Jonsson EN, Mansson B, Heinegard D, Saxne T: Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis. Ann Rheum Dis. 2006, 65: 1490-1494. 10.1136/ard.2005.051292.PubMedCentralCrossRefPubMed
28.
Manicourt DH, Poilvache P, Nzeusseu A, van EA, Devogelaer JP, Lenz ME, Thonar EJ: Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest. Arthritis Rheum. 1999, 42: 1861-1869. 10.1002/1529-0131(199909)42:9<1861::AID-ANR10>3.0.CO;2-I.CrossRefPubMed
29.
Engstrom-Laurent A: Changes in hyaluronan concentration in tissues and body fluids in disease states. Ciba Found Symp. 1989, 143: 233-240.PubMed
30.
Williams FM, Andrew T, Saxne T, Heinegard D, Spector TD, Mac-Gregor AJ: The heritable determinants of cartilage oligomeric matrix protein. Arthritis Rheum. 2006, 54: 2147-2151. 10.1002/art.21931.CrossRefPubMed
31.
Charni-Ben Tabassi N, Garnero P: Monitoring cartilage turnover. Curr Rheumatol Rep. 2007, 9: 16-24. 10.1007/s11926-007-0017-y.CrossRefPubMed
32.
Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA: Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis. 1984, 43: 8-17.PubMedCentralCrossRefPubMed
33.
Brennan P, Harrison B, Barrett E, Chakravarty K, Scott D, Silman AJ: A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. BMJ. 1996, 313: 471-476.PubMedCentralCrossRefPubMed
34.
Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ: Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum. 2002, 46: 906-912. 10.1002/art.10167.CrossRefPubMed
35.
Rantapaa-Dahlqvist S: Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand J Rheumatol. 2005, 34: 83-96. 10.1080/03009740510017689.CrossRefPubMed
36.
Nell V, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, Smolen JS, Steiner G: Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 1731-1736. 10.1136/ard.2005.035691.PubMedCentralCrossRefPubMed
37.
van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, van Venrooij WJ, Verweij CL, Toes RE, de Vries RR: Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum. 2004, 50: 2113-2121. 10.1002/art.20316.CrossRefPubMed
38.
De Rycke L, Verhelst X, Kruithof E, Bosch van den F, Hoffman IE, Veys EM, de Keyser F: Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 299-302. 10.1136/ard.2004.023523.PubMedCentralCrossRefPubMed
39.
Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, Wei N, Boyle DL: Assessment of rituximab's immunomodulatory synovial effects (the ARISE trial). I: clinical and synovial biomarker results. Ann Rheum Dis. 2007, 67: 402-408. 10.1136/ard.2007.074229.PubMedCentralCrossRefPubMed
40.
Heijde Van der DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, Putte van de LB: Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol. 1992, 31: 519-525. 10.1093/rheumatology/31.8.519.CrossRefPubMed
41.
Rooney M, Condell D, Quinlan W, Daly L, Whelan A, Feighery C, Bresnihan B: Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum. 1988, 31: 956-963. 10.1002/art.1780310803.CrossRefPubMed
42.
Bresnihan B, Tak PP: Synovial tissue analysis in rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol. 1999, 13: 645-659. 10.1053/berh.1999.0051.CrossRefPubMed
43.
Bresnihan B, Gerlag DM, Rooney T, Smeets TJ, Wijbrandts CA, Boyle D, Fitzgerald O, Kirkham BW, McInnes IB, Smith M, Ulfgren AK, Veale DJ, Tak PP: Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol. 2007, 34: 620-622.PubMed
44.
Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, McInnes IB, Bresnihan B, Tak PP: Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 834-838. 10.1136/ard.2004.029751.PubMedCentralCrossRefPubMed
45.
Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, Morgan S, Nash AF, Tak PP: Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum. 2004, 50: 3783-3791. 10.1002/art.20664.CrossRefPubMed
46.
Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, Bosch van den F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP: A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006, 54: 2387-2392. 10.1002/art.21975.CrossRefPubMed
47.
Vos K, Thurlings RM, Wijbrandts CA, van SD, Gerlag DM, Tak PP: Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 2007, 56: 772-778. 10.1002/art.22400.CrossRefPubMed
48.
Kraan MC, Versendaal H, Jonker M, Bresnihan B, Post WJ, t Hart BA, Breedveld FC, Tak PP: Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum. 1998, 41: 1481-1488. 10.1002/1529-0131(199808)41:8<1481::AID-ART19>3.0.CO;2-O.CrossRefPubMed
49.
Haupl T, Yahyawi M, Lubke C, Ringe J, Rohrlach T, Burmester GR, Sittinger M, Kaps C: Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007, 12: 328-340. 10.1177/1087057107299261.CrossRefPubMed
50.
Gerlag DM, Boyle DL, Rosengren S, Nash T, Tak PP, Firestein GS: Real-time quantitative PCR to detect changes in synovial gene expression in rheumatoid arthritis after corticosteroid treatment. Ann Rheum Dis. 2007, 66: 545-547. 10.1136/ard.2006.059790.PubMedCentralCrossRefPubMed
51.
van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH: Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis. 1995, 54: 674-677.PubMedCentralCrossRefPubMed
52.
Eastgate JA, Symons JA, Wood NC, Grinlinton FM, diGiovine FS, Duff GW: Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet. 1988, 2: 706-709. 10.1016/S0140-6736(88)90185-7.CrossRefPubMed
53.
Knudsen LS, Christensen IJ, Lottenburger T, Svendsen MN, Nielsen HJ, Nielsen L, Hørslev-Petersen K, Jensen JE, Kollerup G, Johansen JS: Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers. 2008, 13: 59-78. 10.1080/13547500701615017.CrossRefPubMed
54.
Weyand CM, Klimiuk PA, Goronzy JJ: Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes. Springer Semin Immunopathol. 1998, 20: 5-22. 10.1007/BF00831996.CrossRefPubMed
55.
Tak PP: Analyzing synovial tissue samples. What can we learn about early rheumatoid arthritis, the heterogeneity of the disease, and the effects of treatment?. J Rheumatol. 2005, 32 (Suppl 72): 25-26.
56.
Veale DJ, Ritchlin C, Fitzgerald O: Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005, 64 (Suppl 2): ii26-ii29. 10.1136/ard.2004.031740.PubMedCentralPubMed
57.
Francois RJ, Neure L, Sieper J, Braun J: Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006, 65: 713-720. 10.1136/ard.2005.037465.PubMedCentralCrossRefPubMed
58.
Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS: Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997, 24: 518-523.PubMed
59.
Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, Kunaver M, Zenz P, Smolen JS: Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford). 1999, 38: 202-213. 10.1093/rheumatology/38.3.202.CrossRef
60.
Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, Lord JM, Gordon C, Buckley CD, Salmon M: Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther. 2005, 7: R784-R795. 10.1186/ar1733.PubMedCentralCrossRefPubMed
61.
Gabay C, Silacci P, Genin B, Mentha G, Le CC, Guerne PA: Soluble interleukin-6 receptor strongly increases the production of acute-phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes. Eur J Immunol. 1995, 25: 2378-2383. 10.1002/eji.1830250838.CrossRefPubMed
62.
Dawes PT, Fowler PD, Clarke S, Fisher J, Lawton A, Shadforth MF: Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol. 1986, 25: 44-49. 10.1093/rheumatology/25.1.44.CrossRefPubMed
63.
Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS: Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res. 2005, 7: R796-R806. 10.1186/ar1740.CrossRef
64.
van Leeuwen MA, van Rijswijk MH, Sluiter WJ, van Riel PL, Kuper IH, Putte van de LB, Pepys MB, Limburg PC: Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol. 1997, 24: 20-27.PubMed
65.
Smolen JS, Heijde Van Der DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group: Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum. 2006, 54: 702-710. 10.1002/art.21678.CrossRefPubMed
66.
St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46: 1451-1459. 10.1002/art.10302.CrossRefPubMed
67.
Duff GW: Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol Suppl. 1994, 100: 9-19. 10.3109/03009749409095197.CrossRefPubMed
68.
Otterness IG: The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum. 1994, 24: 91-104. 10.1016/S0049-0172(05)80003-4.CrossRefPubMed
69.
Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999, 163: 1521-1528.PubMed
70.
Barrera P, Boerbooms AM, Putte van de LB, Meer van der JW: Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum. 1996, 25: 234-253. 10.1016/S0049-0172(96)80035-7.CrossRefPubMed
71.
Lassere MN, Johnson KR, Boers M, Tugwell P, Brooks P, Simon L, Strand V, Conaghan PG, Ostergaard M, Maksymowych WP, Landewe R, Bresnihan B, Tak PP, Wakefield R, Mease P, Bingham CO, Hughes M, Altman D, Buyse M, Galbraith S, Wells G: Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol. 2007, 34: 607-615.PubMed
72.
American College of Rheumatology Committee to Reevaluate Improvement Criteria: A proposed revision to the ACR20: the hybrid measure of ACR response [abstract]. Arthritis Rheum. 2007, 57: 193-202. 10.1002/art.22552.CrossRef
73.
Soubrier M, Zerkak D, Gossec L, Ayral X, Roux C, Dougados M: Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice?. J Rheumatol. 2006, 33: 1243-1246.PubMed
74.
Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T: Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000, 191: 275-286. 10.1084/jem.191.2.275.PubMedCentralCrossRefPubMed
75.
Devlin RD, Reddy SV, Savino R, Ciliberto G, Roodman GD: IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J Bone Miner Res. 1998, 13: 393-399. 10.1359/jbmr.1998.13.3.393.CrossRefPubMed
76.
Ragab AA, Nalepka JL, Bi Y, Greenfield EM: Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. Am J Physiol Cell Physiol. 2002, 283: C679-C687.CrossRefPubMed
77.
Lee ZH, Lee SE, Kim CW, Lee SH, Kim SW, Kwack K, Walsh K, Kim HH: IL-1alpha stimulation of osteoclast survival through the PI 3-kinase/Akt and ERK pathways. J Biochem (Tokyo). 2002, 131: 161-166.CrossRef
78.
Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL: TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000, 106: 1481-1488. 10.1172/JCI11176.PubMedCentralCrossRefPubMed
79.
Smolen JS, Han C, Bala M, Maini RN, Kalden JR, Heijde van der D, Breedveld FC, Furst DE, Lipsky PE, ATTRACT Study Group: Evidence of radiographic benefit of infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of the ATTRACT Trial. Arthritis Rheum. 2005, 52: 1020-1030. 10.1002/art.20982.CrossRefPubMed
80.
Landewe R, Heijde van der D, Klareskog L, van Vollenhoven R, Fatenejad S: Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum. 2006, 54: 702-710. 10.1002/art.22143.CrossRef
81.
St Clair EW, Heijde van der DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004, 50: 3432-3443. 10.1002/art.20568.CrossRefPubMed
82.
Klareskog L, Heijde van der D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M, TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004, 363: 675-681. 10.1016/S0140-6736(04)15640-7.CrossRefPubMed
83.
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT: The PREMIER study – a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006, 54: 26-37. 10.1002/art.21519.CrossRefPubMed
84.
Redlich K, Görtz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, Bergmeister H, Kollias G, Steiner G, Smolen JS, Schett G: Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol. 2004, 164: 543-555.PubMedCentralCrossRefPubMed
85.
Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, Heide van der D, Landewe R, Lacey D, Richards WG, Schett G: Dickkopf-1 is a master regulator of joint remodeling [abstract]. Nat Med. 2007, 13: 156-163. 10.1038/nm1538.CrossRefPubMed
86.
Smolen JS, Han C, Heijde van der D, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Aletaha D, Baker D, Han J, Bala M, St Clair EW: Infliximab inhibits radiographic progression regardless of disease activity at baseline and following treatment in patients with early active rheumatoid arthritis [abstract]. Arthritis Rheum. 2006, 54 (Suppl): S231-
87.
Aletaha D, Funovits J, Keystone EC, Smolen JS: Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 2007, 56: 3226-3235. 10.1002/art.22943.CrossRefPubMed
88.
Schoels M, Funovits J, Muellner J, Smolen JS, Aletaha D: Disease activity at baseline and early treatment response predict long-term success of therapy in rheumatoid arthritis – results from an observational study [abstract]. Arthritis Rheum. 2007, 56 (Suppl): S186-
89.
Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS: Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis. 2004, 63: 1269-1275. 10.1136/ard.2003.015131.PubMedCentralCrossRefPubMed
90.
Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS: Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis. 2002, 61: 290-297. 10.1136/ard.61.4.290.PubMedCentralCrossRefPubMed
91.
Goronzy JJ, Matteson EL, Fulbright JW, Warrington KJ, Chang-Miller A, Hunder GG, Mason TG, Nelson AM, Valente RM, Crowson CS, Erlich HA, Reynolds RL, Swee RG, O'Fallon WM, Weyand CM: Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis Rheum. 2004, 50: 43-54. 10.1002/art.11445.CrossRefPubMed
92.
Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004, 200: 277-285. 10.1084/jem.20040165.PubMedCentralCrossRefPubMed
93.
Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P: Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006, 54: 3761-3773. 10.1002/art.22190.CrossRefPubMed
94.
Taylor PC: Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology (Oxford). 2005, 44: 721-728. 10.1093/rheumatology/keh524.CrossRef
95.
Wakefield RJ, D'Agostino MA, Iagnocco A, Filippucci E, Backhaus M, Scheel AK, Joshua F, Naredo E, Schmidt WA, Grassi W, Moller I, Pineda C, Klauser A, Szkudlarek M, Terslev L, Balint P, Bruyn GA, Swen WA, Jousse-Joulin S, Kane D, Koski JM, O'Connor P, Milutinovic S, Conaghan PG, OMERACT Ultrasound Group: The OMERACT Ultrasound Group: status of current activities and research directions. J Rheumatol. 2007, 34: 848-851.PubMed
96.
Herwig R, Lehrach H: Expression profiling of drug response – from genes to pathways. Dialogues Clin Neurosci. 2006, 8: 283-293.PubMedCentralPubMed
97.
Weljie AM, Dowlatabadi R, Miller BJ, Vogel HJ, Jirik FR: An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. J Proteome Res. 2007, 6: 3456-3464. 10.1021/pr070123j.CrossRefPubMed
98.
99.
Firestein GS, Alvaro-Gracia JM, Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol. 1990, 144: 3347-3353.PubMed
Metadaten
Titel
The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
verfasst von
Josef S Smolen
Daniel Aletaha
Johannes Grisar
Kurt Redlich
Günter Steiner
Oswald Wagner
Publikationsdatum
01.06.2008
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 3/2008
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar2418

Weitere Artikel der Ausgabe 3/2008

Arthritis Research & Therapy 3/2008 Zur Ausgabe

Letter

Carotid intima-media thickness and endothelial function: useful surrogate markers for establishing cardiovascular risk in patients with inflammatory rheumatic disease

Research article

Leg-length inequality is not associated with greater trochanteric pain syndrome

Research article

Leukocyte numbers and function in subjects eating n-3 enriched foods: selective depression of natural killer cell levels

Research article

DREAM is reduced in synovial fibroblasts of patients with chronic arthritic pain: is it a suitable target for peripheral pain management?

Research article

Cigarette smoking associates with body weight and muscle mass of patients with rheumatoid arthritis: a cross-sectional, observational study

Commentary

Arthritis gene therapy's first death

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise